zoledronic acid has been researched along with Kidney Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| de Roij van Zuijdewijn, C; Florquin, S; Roelofs, J; van Dorp, W; Verburgh, K | 1 |
| Chen, L; Cheng, L; Chi, W; Deng, H; Feng, Y; Ge, M; Hu, X; Huang, Y; Huo, Y; Kuang, W; Lan, Z; Li, L; Liu, X; Liu, Y; Luo, M; Ma, Z; Siegenthaler, JA; Sun, K; Xi, Q; Xu, L; Yang, J; Zhang, B; Zhang, Y; Zhao, X | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kanellias, N; Terpos, E | 1 |
| Chai, K; Jiang, Y; Lan, Z; Liu, X | 1 |
| Allen, MR; Chen, NX; Gattone, VH; Moe, SM | 1 |
| Arellano, J; Bahl, A; Body, JJ; Gatta, F; Hauber, AB; Haynes, I; Hechmati, G; Mohamed, AF; Qian, Y; von Moos, R | 1 |
| Markowitz, GS; Perazella, MA | 1 |
| Ericson, S; Gruia, G; Hohneker, J | 1 |
| Berenson, JR; Bolejack, V; Crowley, J; Farber, CM; Flinn, IW; Gravenor, DS; Hilger, JD; Makary, A; Morganstein, N; Nassir, Y; Sanani, S; Sefaradi, A; Shamouelian, A; Staszewski, H; Swift, RA; Tiffany, NM; Upadhyaya, GH; Yang, HH; Yellin, O | 1 |
| Hirschberg, R | 2 |
| Atzpodien, E; Bauss, F; Pfister, T | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA | 1 |
| Barnett, JB; de Lemos, ML; Hu, F; Levin, A; Moravan, V; O'Reilly, SE; Taylor, SC | 1 |
4 review(s) available for zoledronic acid and Kidney Diseases
| Article | Year |
|---|---|
Bisphosphonate nephropathy: A case series and review of the literature.
Topics: Animals; Diphosphonates; Humans; Imidazoles; Kidney Diseases; Pamidronate; Rats; Zoledronic Acid | 2021 |
Management of multiple myeloma bone disease: impact of treatment on renal function.
Topics: Bone Density Conservation Agents; Bone Diseases; Disease Management; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid | 2018 |
Bisphosphonate nephrotoxicity.
Topics: Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Kidney Cortex Necrosis; Kidney Diseases; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid | 2008 |
Renal complications from bisphosphonate treatment.
Topics: Acute Kidney Injury; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney; Kidney Diseases; Nephrotic Syndrome; Pamidronate; Risk Factors; Zoledronic Acid | 2012 |
10 other study(ies) available for zoledronic acid and Kidney Diseases
| Article | Year |
|---|---|
Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
Topics: Animals; Benzamides; Cell Line; Coenzyme A Ligases; Dioxoles; Epithelial Cells; Fatty Acids; Fenofibrate; Fibrosis; Humans; Kidney Diseases; Kidney Tubules; Lipid Metabolism; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidation-Reduction; Transforming Growth Factor beta; Zoledronic Acid | 2018 |
Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells.
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Bone Density Conservation Agents; Cell Line; Creatinine; Glutathione; Histamine; Humans; Kidney; Kidney Diseases; Male; Rats, Sprague-Dawley; Reactive Oxygen Species; Zoledronic Acid | 2019 |
Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
Topics: Animals; Bone Diseases; C-Reactive Protein; Calcium; Dental Cementum; Dental Enamel; Diphosphonates; Disease Models, Animal; Heterozygote; Imidazoles; Inflammation; Kidney Diseases; Male; Mandible; Parathyroid Hormone; Periodontitis; Phenotype; Rats; Tomography, X-Ray Computed; X-Ray Microtomography; Zoledronic Acid | 2013 |
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Choice Behavior; Denosumab; Diphosphonates; Female; France; Germany; Humans; Imidazoles; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Pain; Patient Participation; Patient Preference; RANK Ligand; Treatment Outcome; United Kingdom; Zoledronic Acid | 2015 |
FDA drug information that never reaches clinicians.
Topics: Diphosphonates; Drug Approval; Drug Industry; Drug Labeling; Humans; Hypercalcemia; Imidazoles; Kidney Diseases; United States; United States Food and Drug Administration; Zoledronic Acid | 2010 |
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2011 |
The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.
Topics: Acetylglucosamine; Animals; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Glutathione Transferase; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney Diseases; L-Lactate Dehydrogenase; Rats; Rats, Wistar; Urea; Zoledronic Acid | 2003 |
Nephrotoxicity of third-generation, intravenous bisphosphonates.
Topics: Animals; Diphosphonates; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney Diseases; Kidney Tubules, Proximal; Rats; Zoledronic Acid | 2004 |
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Drug Monitoring; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prevalence; Registries; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |